GSK (LON:GSK) Earns “Hold” Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reaffirmed by investment analysts at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday, Digital Look reports. They presently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential upside of 12.39% from the company’s previous close.

GSK has been the subject of a number of other research reports. Berenberg Bank increased their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research report on Tuesday, September 15th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 1,975 price objective on shares of GSK in a research report on Tuesday, September 8th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of GBX 2,064.38.

GSK Stock Performance

Shares of LON GSK traded down GBX 15.50 during midday trading on Tuesday, reaching GBX 1,779.50. 5,327,285 shares of the company traded hands, compared to its average volume of 12,800,099. The company has a market cap of £71.30 billion, a price-to-earnings ratio of 15.11, a PEG ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The stock has a 50-day moving average price of GBX 1,882.52 and a 200 day moving average price of GBX 1,942.08. GSK has a 52 week low of GBX 1,592 and a 52 week high of GBX 2,282.

GSK (LON:GSK) last issued its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. Sell-side analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction dated Friday, September 18th. The shares were bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal purchased 637 shares of GSK stock in a transaction that occurred on Friday, September 18th. The shares were acquired at an average price of GBX 4,985 per share, with a total value of £31,754.45. Over the last 90 days, insiders have purchased 2,144 shares of company stock worth $6,009,566. 0.20% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.